

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
7 June 2001 (07.06.2001)

PCT

(10) International Publication Number
WO 01/40196 A1

(51) International Patent Classification⁷: C07D 239/84, A61K 31/517

(21) International Application Number: PCT/GB00/04561

(22) International Filing Date:
29 November 2000 (29.11.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
09/452,008 30 November 1999 (30.11.1999) US

(71) Applicant (for all designated States except US):
ROBERTS LABORATORIES INC. [US/US]; Meridian Center II, Four Industrial Way West, Eatontown, NJ 07724-2274 (US).

(72) Inventor; and

(75) Inventor/Applicant (for US only): **LANG, Philip, Charles** [US/US]; 216 Edgemere Drive, Toms River, NJ 08755 (US).

(74) Agents: **WOODMAN, Derek et al.**; Frank B. Dehn & Co., 179 Queen Victoria Street, London EC4V 4EL (GB).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AT (utility model), AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, CZ (utility model), DE, DE (utility model), DK, DK (utility model), DM, DZ, EE, EE (utility model), ES, FI, FI (utility model), GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KR (utility model), KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK (utility model), SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:


- With international search report.
- Before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 01/40196 A1

(54) Title: 2-AMINO-5,6-DIHALO-3,4-DIHYDROQUINAZOLINES WITH BLOOD PLATELET REDUCING PROPERTIES



(E)

(57) Abstract: Compounds of formula (E) (wherein X and Y, which may be the same or different, each represents Cl, Br or F) and tautomers thereof have been found to have enhanced platelet count reducing properties. Also provided are methods for synthetically making the compounds of formula (E) and pharmaceutically acceptable addition salts thereof and a method of reducing the platelet count in patient by administering to the patient a platelet reducing effective amount of a compound of formula (E) preferably together with a pharmaceutically acceptable carrier. A pharmaceutical composition is also provided which contains a compound of formula (E) as the active ingredient together with pharmaceutically acceptable excipients. Further provided is a compound of formula (E) for use in therapy and the use of a compound of formula (E) for preparing a medicament for reducing platelet count in a patient.


- 1 -

2-AMINO-5,6-DIHALO-3,4-DIHYDROQUINAZOLINES WITH BLOOD PLATELET REDUCING PROPERTIES

5 This invention relates to certain 2-amino-5,6-dihalo-3,4-dihydroquinazolines of use in the treatment of thrombocythemia, secondary to myeloproliferative diseases, such as Essential Thrombocythemia (ET), Polycythemia Vera (PV), Chronic Myelogenous Leukemia
10 (CML) and Other Myeloproliferative Diseases (OMPD).

 Anagrelide, which is chemically 6,7-dichloro-1,5-dihydroimidazo-[2,1-b]-quinazolin-2(3H)-one, is indicated for the treatment of patients with thrombocythemia, secondary to myeloproliferative
15 diseases, such as Essential Thrombocythemia (ET), Polycythemia Vera (PV), Chronic Myelogenous Leukemia (CML), and Other Myeloproliferative Diseases (OMPD).

 The formula for Anagrelide is:



25 The major clinical action of Anagrelide is to decrease and maintain the platelet count within normal limits. The most common adverse effects associated with the use of Anagrelide are related to its vasodilatory
30 and positive inotropic effects. Cardiovascular side effects associated with the use of Anagrelide have included vasodilation (<5%), tachycardia (7.5%), palpitations (26.1%), and congestive heart failure (1.5%).

35 A study by Gaver et al. (1981) "Clinical Pharmacology and Therapeutics", 29, 381-392, demonstrated that Anagrelide was extensively metabolized

- 2 -

by human subjects to a minimum of at least four to five compounds excreted in the urine and that peak plasma concentrations of the parent drug were only 6 ng/mL. It was reported that very little of the Anagrelide dose


5 (<1%) was excreted as unchanged drug in the urine.

These studies raised the possibility that the thrombocytopenia observed with Anagrelide may be due to a metabolite rather than the parent drug. In the Gaver study the use of ^{14}C -anagrelide indicated by HPLC a

10 minimum of four to five metabolites which accounted for over 75% of the urinary radioactivity. It was concluded that the antiaggregation activity observed in humans is possibly related to the presence of Anagrelide and an active metabolite(s).

15 U.S. Patent No. 3,932,407 and its Reissue Patent No. Re. 31,617, which patents are hereby incorporated by reference, disclose Anagrelide type compounds of the formula:

20




25 in which R^1 is H, phenyl or lower alkyl, R^2 and R^3 when alike are H, chloro, bromo, fluoro, lower alkyl, hydroxy or lower alkoxy, R^2 and R^3 when different are H, chloro, bromo, fluoro, SO_3H , CF_3 , hydroxy, nitro, amino, phenyl, lower alkyl of 1 to 3 carbon atoms or lower alkoxy of 1

30 to 3 carbon atoms, or when taken together R^2 and R^3 are methylenedioxy or the residue of phenyl ring, and n is an integer of 1 or 2; and pharmaceutically acceptable acid addition salts thereof. The compounds, which are disclosed as hypotensive, blood platelet reducer and/or

35 bronchodilator agents, are prepared *inter alia* by a multistep process ending in the reaction of CNBr with an ethanolic solution of a compound of the formula:


- 3 -



in which R^1 , R^2 , R^3 and n are as described above, and R^4 is lower alkyl.

10 Anagrelide may be prepared directly from a lower alkyl-N-(6-amino-2,3-dichlorobenzyl)glycine of Formula (C) by reaction in an alcoholic solution with CNBr. U.S. Patent No. 4,146,718 incorporated herein by reference, discloses an improved process whereby higher yields of
 15 Anagrelide may be obtained by reacting a compound of Formula (C) with, for example, CNBr, CNCl or CNI in an inert, aprotic organic solvent and isolating the novel intermediate of Formula D:

20



25

wherein R^4 is (lower)alkyl and X is chloro, bromo or iodo. In a preferred embodiment X is bromo and R^4 is methyl, ethyl, n-propyl, isopropyl or n-butyl. In a more preferred embodiment X is bromo and R^4 is methyl, ethyl
 30 or n-propyl. In a most preferred embodiment X is bromo and R^4 is ethyl.

Intermediate compound (D) is then treated with a base to produce the Anagrelide compound of Formula A.

35 As reported in U.S. Patent No. 4,146,718, *supra*, although the compounds of Formula (D) are primarily intended as intermediates in the preparation of Anagrelide, they themselves have blood platelet

- 4 -


antiaggregative properties.

It is an objective of the present invention to provide alternative compounds having enhanced platelet reducing properties.

5 A further object of the invention is to provide a method for reducing the platelet count in a patient by administering a platelet reducing amount of a compound having enhanced platelet reducing properties preferably with a pharmaceutical carrier in a unit dose.


10 It is yet another object of the present invention to provide a pharmaceutical composition containing a compound effective for reducing the platelet count together with pharmaceutically acceptable excipients.

According to one aspect of the present invention
15 there are provided compounds of the formula (E)



(wherein X and Y, which may be the same or different, each represents Cl, Br or F) and tautomers thereof.

25 The compounds of formula (E) may exist in tautomeric form as compounds of formula (F)



The invention also extends to pharmaceutically acceptable acid addition salts of compounds of formula
35 (E) and their tautomers.

If the compounds of formula E and their tautomers are initially obtained as acid addition salts, these may


- 5 -

be converted into the corresponding free dihydroquinazolines according to procedures well known to those skilled in the art. The free dihydroquinazolines may themselves be converted into different acid addition salts by reaction with inorganic or organic acids. Suitable acids include, for example, hydrochloric, hydrobromic, sulfuric, phosphoric, fumaric, succinic, lactic, citric, tartaric, maleic and methanesulfonic acids.

10 In a preferred embodiment Y and X are both Cl and the compound is 2-amino-5,6-dichloro-3,4-dihydroquinazoline.

Viewed from another aspect, the invention provides a method for making a compound of the formula:


15



20

in the form of an HZ addition salt which comprises reacting a compound of formula (K)

25




(wherein X and Y are as defined in claim 1) with a compound of formula CNZ (wherein Z is Cl, Br or F).

30

Compound (K) may, for example, be obtained by reduction of a compound of formula (J)

35




- 6 -

(wherein X and Y are as previously defined).

Compound (J) may, for example, be obtained by reduction of a compound of formula (I)

5




10

(wherein X and Y are as previously defined).

Compound (I) may, for example, be obtained by reacting a compound of formula (H)

15




20

(wherein X and Y are as are as previously defined and W represents Cl, Br or F) under cyanation conditions.

Compound (H) may, for example, be obtained by nitrating a compound of formula (G)

25



30

(wherein X, Y and W are as previously defined).


Compound (J) may, for example, also be obtained by aminating a compound of formula (O)

35

- 7 -


(wherein X and Y are as previously defined and V is Cl, Br or F).

Compound (O) may, for example, be obtained by sequentially hydroxylating and halogenating, preferably
5 in *in situ* sequential reactions, a compound of formula (M) by way of intermediate (N)



(wherein X and Y are as previously defined).

15 Compound (M) may, for example, be obtained by nitrating a compound of formula (L)



(wherein X and Y are as previously defined).

Compound (J) may, for example, also be obtained by reductive amination of compound (M).

25 Viewed from a further aspect, the invention provides a method for reducing the platelet count in a patient which comprises administering to the patient a platelet reducing effective amount of a compound of the formula of compound (E), preferably in combination with
30 a pharmaceutical carrier. The compound is administered in a unit dosage form typically in the form of a capsule, tablet, enteric coated tablet, intravenous formulation or nasal spray.

35 Viewed from a still further aspect, of the invention a pharmaceutical composition is provided containing as the active ingredient at least one compound as in formula (E) together with pharmaceutical


- 8 -

acceptable excipients such as mannitol and methyl cellulose. The pharmaceutical composition is in a unit dosage form which is administered to patients taking the pharmaceutical composition.

5 The invention also provides a compound of formula (E) for use in therapy; and the use of a compound of formula (E) for preparing a medicament for reducing platelet count in a patient.

Compounds of the formula (E)

10



15

(wherein X and Y, which may be the same or different, each represent Cl, Br or F); tautomers thereof and pharmaceutically acceptable addition salts thereof have
20 been found to have enhanced platelet reducing properties.

2-Amino-5,6-dichloro-3,4-dihydroquinazoline (compound (E) wherein X and Y are both Cl) is the preferred compound for use in reducing the platelet
25 count in patients and is preferably provided as the hydrobromide salt which is water soluble. This is to be compared with Anagrelide hydrochloride which is nearly insoluble in water,

2-Amino-5,6-dichloro-3,4-dihydroquinazoline has
30 been synthesized and has been found to be an active molecule for causing reduction of platelet counts, without the side effects of inotropy and haemorrhaging associated with Anagrelide. Only very mild antihypertensive activity was noticed during
35 cardiovascular screening of the compound.

As shown below in the Examples, a preferred process is set forth for making 2-amino-5,6-dichloro-3,4-

- 9 -

dihydroquinazoline from commercially available starting materials. In one process 1,2,3-trichlorobenzene is used as the starting material and is nitrated using, for example, nitric/sulfuric acids to form 1,2,3-trichloro-4-nitrobenzene. This compound is then reacted with a cyanating agent such as CuCN to form 2,3-dichloro-6-nitrobenzonitrile. The nitrile is then reacted under reducing conditions using for example B_2H_6 to form 2,3-dichloro-6-nitrobenzylamine HCl which is then reduced and reacted with CNX to form the desired compound.

In another process, 2,3-dichlorobenzaldehyde is reacted to form 2,3-dichloro-6-nitrobenzaldehyde. The aldehyde is then reacted to form the alcohol and *in situ* reacted to form the corresponding halomethyl compound. The halomethyl compound is then reacted to form the benzylamine. The benzylamine is reduced to form the diamine and the diamine reacted with CNX to form the desired compound. In another process the 2,3-dichloro-6-nitrobenzaldehyde (above) is reductively aminated to the benzylamine and the process continued to form 2-amino-5,6-dichloro-3,4-dihydroquinazoline.

EXAMPLES

A metabolite of Anagrelide was isolated from human urine and purified by reversed-phase HPLC. Structural characterization was carried out by the use of mass spectrometry and 1H -NMR spectroscopy. Positive liquid secondary ion mass spectrometry provided an exact mass of the protonated molecule as 216.0080 and a calculated chemical composition of $C_8H_7N_3Cl_2$. The 1H -NMR spectrum indicated that the compound contained two ortho coupled aromatic protons and two benzylic protons located on a quinazoline ring. Capillary LC/electrospray mass spectrometry showed that the metabolite was a homogeneous single compound which gave an intense protonated molecular ion at m/z 216 with a chlorine

- 10 -

isotope peak at m/z 218. In source fragmentation resulted in the generation of structurally significant fragment ions including the loss of a primary amino group and cleavage of the quinazoline ring. Based on these data the metabolite was identified as 2-amino-5,6-dichloro-3,4-dihydroquinazoline. The structure of the metabolite was confirmed by comparison with a synthesized sample.

Metabolism of Anagrelide was examined in a number of *in vitro* systems including rat and human liver microsomes, human whole blood, human bone marrow cells and rat intestinal mucosa. Surprisingly, under all of the conditions that were tried, Anagrelide was completely resistant to metabolism. It appears that *in vivo* metabolism occurs by a route that cannot be readily mimicked *in vitro*. It is hypothesized that the first step of *in vivo* metabolism involves hydroxylation of the carbon α to the carbonyl followed by amide hydrolysis and loss of the elements of glyoxylic acid.

In a recent pharmacokinetic and excretion study of [^{14}C] Anagrelide to Rhesus Monkeys, no human metabolite (2-amino-5,6-dichloro-3,4-dihydroquinazoline) was detected, showing that humans uniquely metabolize Anagrelide.

Preparation of 2-amino-5,6-dichloro-3,4-dihydroquinazoline hydrobromide from 2,3-dichlorobenzaldehyde

Preparation of 2,3-dichloro-6-nitrobenzaldehyde

A solution of 40 g of 2,3-dichlorobenzaldehyde in 160 mL of concentrated sulfuric acid (95-98% w/w) is heated to 40°C and stirred to form a solution, then cooled to 20-25°C. Concentrated nitric acid (69-71% w/w; 24.7 g) is added to this solution over 20 minutes (an ice bath is used to maintain a reaction temperature of 20-30°C). The reaction mixture is stirred at room

- 11 -

temperature for 1 hour, and then added in portions to 600 mL of water. The resulting suspension is stirred for 2 hours and filtered. The filter cake is washed (3 x 50 mL water). The filter cake is agitated with 200 mL of water for 2 hours and filtered. The filter cake is washed (3 x 50 mL of water) and dried in vacuo to give a mixture of the title product and the isomer, 2,3-dichloro-5-nitrobenzaldehyde

The crude product is triturated with hexane for 3 hours and filtered. The filter cake is washed with hexane (2 x 70 mL). This trituration procedure is repeated with fresh hexane until the 5-nitro isomer is removed. The filter cake is then dried in vacuo to give the purified title product in 44 to 50% yield.

15

Preparation of 2,3-dichloro-6-nitrobenzylalcohol

A solution of 40 g of 2,3-dichloro-6-nitrobenzaldehyde in 200 mL of toluene was stirred for five minutes. Then, 7.4 mL of methanol was added and mixing continued until all the solids had dissolved. Separately, a solution of 2.41 g of sodium borohydride in 120 mL of toluene was prepared. The benzaldehyde solution was added by drops to the borohydride solution over 20 minutes to maintain the reaction temperature below 25°C. The reaction mixture was stirred for 24 hours at room temperature under nitrogen. 40 mL of water was added and the mixture stirred for 15 minutes. The aqueous layer was removed and the organic layer washed with water (3 x 40 mL). The organic layer was azeotropically dried using a Dean-Stark trap, and concentrated to 280 mL. The 2,3-dichloro-6-nitrobenzylalcohol was used without further purification.

35 Preparation of 1,2-dichloro-3-chloromethyl-4-nitrobenzene

Under nitrogen, 27.9 mL of triethylamine was added

- 12 -

to the concentrated solution of 2,3-dichloro-6-nitrobenzylalcohol prepared in the previous step. To this solution, 14.6 mL of thionyl chloride was added via an addition funnel over 15 minutes. Following addition, the solution was heated to 45-50°C for 18 hours, then cooled to room temperature under nitrogen. Water and toluene were added to the reaction mixture and the mixture filtered. The filtrate was diluted with water, and the aqueous layer removed. The organic layer was washed with water (4 x 40 mL), and dried by azeotropic distillation. The solution was concentrated to give 1,2-dichloro-3-chloromethyl-4-nitrobenzene which could be used without further purification.

15 Preparation of 2,3-dichloro-6-nitrobenzylamine

Potassium carbonate and 2 equivalents of phthalimide are ground together and heated to reflux with 2 equivalents of 1,2-dichloro-3-chloromethyl-4-nitrobenzene for three hours. Upon cooling, the substituted benzylphthalimide crystallizes and is filtered in 60-80% yield. 2,3-Dichloro-6-nitrobenzylamine is obtained in a 75-95% yield with acid hydrolysis using hydrochloric acid from the substituted benzylphthalimide.

25

Preparation of 2-amino-5,6-dichlorobenzylamine

A solution of 7.131 g of tin (II) chloride dihydrate in 4.7 L of concentrated hydrochloric acid was prepared. Separately, 1.631 g of 2,3-dichloro-6-nitrobenzylamine hydrochloride was dissolved in 9.5 L of concentrated hydrochloric acid. The solution of the amine was added to the tin chloride solution over 1-2 hours to maintain the reaction temperature below 45°C. The mixture was stirred for 2 hours at 40-45°C in a warm water bath, and cooled in an ice/methanol bath to -5°C. The mixture was filtered, and the isolated solids slurried with 13 L water, 6.5 kg ice, and 6 L methylene

- 13 -

chloride. Sodium hydroxide (50% aqueous solution) was added until pH > 12, and the organic layer was removed. The aqueous phase was extracted with methylene chloride (2 x 6 L), and the combined organic layers washed with water (6 L portions) until pH 7-8. The organic layers were dried over magnesium sulfate (500 g) and charcoal (200 g) for 16 hours, and filtered. The filtrate was concentrated to an oil, and crystallized from isopropanol at -20°C to give 2-amino-5,6-dichlorobenzylamine in 58 to 96% yield.

Preparation of 2-amino-5,6-dichloro-3,4-dihydroquinazoline

A solution of 2.58 kg of 2-amino-5,6-dichlorobenzylamine in 2.7 L of toluene was prepared at 50-60°. A solution of cyanogen bromide (1.558 kg in 8 L toluene) was added over 2-3 hours. Following addition, the reaction mixture was stirred for 1.5 hours at room temperature, then heated to reflux for 1 hour. The mixture was cooled to room temperature for 12 hours, and the mixture filtered. The filter cake was washed with toluene (2 x 2 L) followed by hexane (2 x 2 L) and dried to give 2-amino-5,6-dichloro-3,4-dihydroquinazoline hydrobromide in 70% to 90% yield.


Characterization of 2-amino-5,6-dichloro-3,4-dihydroquinazoline

Elemental Status

Analysis calculated for $C_8H_7N_3Cl_2 \cdot HBr$: C, 32.35%; H, 2.72%; N, 14.15%; Br, 26.91%; Cl, 23.88%; Found: C, 32.78%; H, 2.73%; N, 13.91%; Br, 27.17%; Cl, 23.90%.

The above method of preparation may be shown by the following equation sequence:

- 14 -



15 * This reaction was run *in situ* with no isolation of the alcohol from the alcoholization reaction.

In another process of the invention the 2,3-dichloro-6-nitrobenzaldehyde formed above (compound (M) wherein X and Y are both Cl) is reductively aminated to form 2,3-dichloro-6-nitrobenzylamine (compound (J) wherein both X and Y are Cl) as follows:

A solution of the aldehyde in methanol is stored for 16 hours at room temperature with 10 equivalents of ammonium hydroxide and 0.5 equivalents of sodium cyanoborohydride. The reaction was quenched by the addition of water and 1N HCl. The product amine was isolated by concentration in a 60-84% yield.

2,3-Dichloro-6-nitrobenzylamine is then reacted as above to form the desired 2-amino-5,6-dichloro-3,4-dihydroquinazoline hydrobromide.

- 15 -

**Preparation of 2-amino-5,6-dichloro-3,4-dihydroquinazoline hydrobromide from
1,2,3-trichlorobenzene**

5 Preparation of 1,2,3-trichloro-4-nitrobenzene

A mixture of 9.0 kg of 1,2,3-trichlorobenzene in 13.32 L of concentrated sulfuric acid is added by drops to a solution of 4.13 L of 70% nitric acid and 4.13 L of concentrated sulfuric acid at 25-30°C. The slurry is
10 stirred for 1.5-2 hours, then poured over 35 kg of ice and filtered. The filter cake is washed (15 L water) and then dissolved in 58 L of ethyl acetate. The organic phase is washed with water, aqueous sodium bicarbonate solution, and aqueous sodium chloride solution. The
15 solution is dried over magnesium sulfate and concentrated to give the title product.

Preparation of 2,3-dichloro-6-nitrobenzonitrile

20 A solution of 1.831 kg of 1,2,3-trichloro-4-nitrobenzene and 0.861 kg of copper cyanide in 1.21 L of *N,N*-dimethylformamide is heated to 155°C for 2 hours, then cooled to room temperature. A solution of 3.24 kg of ferric chloride hexahydrate, 0.806 L of concentrated
25 hydrochloric acid, and 4.87 L of water is added and the solution heated to 65°C for 20 minutes. The mixture is cooled, stirred with 0.55 kg of charcoal and 4 L of toluene, and filtered. The organic phase is separated and the aqueous phase extracted with toluene. The
30 combined toluene layers are washed with water and 6 N HCl, dried and concentrated to give a slurry. The slurry is dissolved in 1.5 L of methanol, and stored at 5°C for 24 hours. The nitrile product is collected by filtration, washed with 1.5 L cold methanol and dried
35 at 40°C.


- 16 -

Preparation of 2,3-dichloro-6-nitrobenzylamine HCl

A solution of 0.213 kg of 2,3-dichloro-6-nitrobenzonitrile in 1.176 L of dry tetrahydrofuran is added to 1.6L of borane-tetrahydrofuran complex (BH₃.THF) between 0-5°C. The solution is stirred for 2 hours at room temperature, heated to 66°C for 2 hours, and then cooled to 15°C, before adding 0.329 L of cold methanol. The mixture is held for 17 hours and evaporated under vacuum to an oil. The oil is dissolved in ethyl acetate, cooled to 0°C and sparged with hydrogen chloride gas. The salt is collected by filtration, washed with cold ethyl acetate, and dried.

As shown above, the nitro group in the above compound is then reduced with SnCl₂/HCl to form 2,3-dichloro-6-nitrobenzylamine HCl (compound (K) wherein both X and Y are Cl) and then reacted with CNBr to make the desired 2-amino-5,6-dichloro-3,4-dihydroquinazoline hydrobromide.

The above reaction sequence starting from 1,2,3-trichlorobenzene is as follows:



35 The effectiveness of 2-amino-5,6-dichloro-3,4-dihydroquinazoline hydrobromide of the invention is shown wherein daily intraperitoneal injection of the

- 17 -

preferred compound in 6- to 8-month old mice resulted in a dose-dependent decrease in circulating platelet levels. Administration of 100 $\mu\text{g}/\text{day}$ of the preferred compound was sufficient to decrease platelet counts within 24-48 hours stabilizing to 50% of normal by day 5. Even at high doses (300 μg), the preferred compound did not alter white blood cell counts, bleeding time or lead to any apparent signs of toxicity or haemorrhaging. A profound inhibition of megakaryocytic endoreplication was achieved at doses 500 times less than those reported for Anagrelide. However, there was no effect on the CD15⁺ myeloid lineage suggesting that even *in vitro* the preferred compound selectively affects megakaryocytic lineage, but unlike Anagrelide, the compound did not inhibit platelet aggregation even at high concentrations (10 $\mu\text{g}/\text{mL}$).


While the present invention has been particularly described, in conjunction with a specific preferred embodiment, it is evident that many alternatives, modifications and variations will be apparent to those skilled in the art in light of the foregoing description. It is therefore contemplated that the appended claims will embrace any such alternatives, modifications and variations as falling within the true scope and spirit of the present invention.

- 18 -

Claims:

1. A compound of the formula:

5



10

(wherein X and Y, which may be the same or different, each represents Cl, Br or F) and tautomers thereof.

2. A compound as claimed in claim 1 wherein both X and Y are Cl.

15


3. A pharmaceutically acceptable addition salt of a compound as claimed in claim 1 or claim 2.

4. A salt as claimed in claim 3 being the HBr salt.

20


5. A method for making a compound of the formula:

25



30 in the form of an HZ addition salt which comprises reacting a compound of formula (K)


35



- 19 -


(wherein X and Y are as defined in claim 1) with a compound of formula CNZ (wherein Z is Cl, Br or F).

6. A method as claimed in claim 5 wherein the compound of formula (K) is obtained by reduction of a compound of formula (J)




(wherein X and Y are as defined in claim 1).

7. A method as claimed in claim 6 wherein the compound of formula (J) is obtained by reduction of a compound of formula (I)



(wherein X and Y are as defined in claim 1).


8. A method as claimed in claim 7 wherein the compound of formula (I) is obtained by reacting a compound of formula (H)



(wherein X and Y are as claimed in claim 1 and W represents Cl, Br or F) under cyanation conditions.

9. A method as claimed in claim 8 wherein the compound of formula (H) is obtained by nitrating a compound of formula (G)

- 20 -




5

(wherein X and Y are as defined in claim 1 and W is as defined in claim 8).

10. A method as claimed in claim 6 wherein the compound of formula (J) is obtained by aminating a compound of formula (O)


15



(wherein X and Y are as defined in claim 1 and V is Cl, Br or F).

- 20 11. A method as claimed in claim 10 wherein the compound of formula (O) is obtained by sequentially hydroxylating and halogenating a compound of formula (M)


25



(wherein X and Y are as defined in claim 1).

- 30 12. A method as claimed in claim 11 wherein the compound of formula (M) is obtained by nitrating a compound of formula (L)

35



- 21 -

(wherein X and Y are as defined in claim 1).

13. A method as claimed in claim 6 wherein the compound
of formula (J) is obtained by reductive amination of a
5 compound of formula (M) as defined in claim 11.

14. A method of reducing platelet count in a patient
which comprises administering to said patient a platelet
reducing effective amount of a compound as claimed in
10 any of claims 1 to 4.

15. A pharmaceutical composition containing as the
active ingredient at least one compound as claimed in
any one of claims 1 to 4 together with one or more
15 pharmaceutically acceptable excipients.

16. A compound as claimed in any one of claims 1 to 4
for use in therapy.

20 17. Use of a compound as claimed in any one of claims 1
to 4 for preparing a medicament for reducing platelet
count in a patient.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 00/04561

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C07D239/84 A61K31/517

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, BEILSTEIN Data, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	CHEMICAL ABSTRACTS, vol. 129, no. 23, 7 December 1998 (1998-12-07) Columbus, Ohio, US; abstract no. 298166, PETRIDES P E ET AL: "Anagrelide, a novel platelet lowering option in essential thrombocythemia: treatment experience in 48 patients in Germany" XP002161852 abstract & EUR. J. HAEMATOL., vol. 61, no. 2, 1998, pages 71-76, ---	1-17
A	US 4 146 718 A (JENKS THOMAS A ET AL) 27 March 1979 (1979-03-27) cited in the application the whole document --- -/--	1-17

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

2 March 2001

Date of mailing of the international search report

26.03.01

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Fink, D

INTERNATIONAL SEARCH REPORT

International Application No
PCT/GB 00/04561

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>US 3 932 407 A (BEVERUNG JR WARREN NEIL ET AL) 13 January 1976 (1976-01-13) cited in the application the whole document -----</p>	1-17

INTERNATIONAL SEARCH REPORT

International application No.
PCT/GB 00/04561

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claim 14 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 00/04561

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 4146718 A	27-03-1979	AU 527748 B	24-03-1983
		AU 4588979 A	18-10-1979
		BE 875475 A	10-10-1979
		CA 1109067 A	15-09-1981
		CA 1137474 A	14-12-1982
		CH 639079 A	31-10-1983
		DE 2914494 A	18-10-1979
		DK 76782 A,B,	22-02-1982
		DK 144779 A,B,	11-10-1979
		DK 316686 A,B,	03-07-1986
		FI 791125 A,B,	11-10-1979
		FI 830150 A,B,	17-01-1983
		FR 2422649 A	09-11-1979
		GB 2018765 A,B	24-10-1979
		GR 72937 A	13-01-1984
		HU 187562 B	28-01-1986
		HU 179424 B	28-10-1982
		IE 48150 B	17-10-1984
		JP 1607560 C	13-06-1991
		JP 2033035 B	25-07-1990
		JP 54135794 A	22-10-1979
		JP 2022276 A	25-01-1990
		JP 3012066 B	19-02-1991
		NL 7902825 A,B,	12-10-1979
		SE 445217 B	09-06-1986
		SE 7903198 A	11-10-1979
		SE 454990 B	13-06-1988
		SE 8404061 A	10-08-1984
		SU 1120923 A	23-10-1984
		YU 83079 A	31-12-1983
		ZA 7901727 A	28-05-1980
US 3932407 A	13-01-1976	US RE31617 E	26-06-1984